Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.6652W HIGH $5.49
Volume
17.17 K
Value Traded
32.67 K
Short % Float
1.7%
-0.5%Week
-5.7%1 Month
-2.3%3 Month
-29.55%6 Month
-4.2%5 Year
-48.05%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
49.06 M
EPS (TTM)
-0.94
P/E Ratio
-
Ent. Value
33.87 M
Total Shares
16.46 M
Float Shares
13.39 M
Insiders
18.67%
Institutions
24.92%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SRTS Catalyst Timeline
Dated clinical, regulatory and corporate events for Sensus Healthcare, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sensus Healthcare, Inc.
3Total events
1Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 1
TBD
T2Reimbursement / Pricing
Subscribe to view catalyst details
Past FDA Catalysts and PDUFA Decisions
How SRTS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Sensus Healthcare, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every SRTS program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sachetta EricDirector | Buy | 27,304 294,784 held | $3.54 | 08/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SRTS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SRTS for Q2 2026. | ||||
SRTS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SRTS ranks across every disease it competes in
Competitive Position is a premium feature
See how SRTS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSRTS News
SRTS▼ -9.5%on this news
Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights
Sensus Healthcare, Inc. reported its financial results for Q2 2026, revealing a revenue of $2.3 million, which marks a significant decrease of $5.0 million from the same quarter in 2025. The decline in revenue is attributed to a reduced number of units sold. The company remains focused on providing effective treatments for various skin conditions.
Read more →SRTSSensus Healthcare to Report Second Quarter 2026 Financial Results and Hold Business Update Conference Call on August 13, 2026
Sensus Healthcare, a medical device company, will announce its financial results for Q2 2026 on August 13, 2026. The company will hold a conference call at 4:30 PM ET to discuss the results and provide a business update. This event will also include a Q&A session for participants.
Read more →SRTSSensus Healthcare Reports First Quarter 2026 Financial Results and Business Highlights
Sensus Healthcare has reported its financial results for the first quarter of 2026, along with key business highlights. The report includes details on revenue and operational performance, although specific figures and insights are not provided in the article. The company continues to focus on its strategic initiatives for growth.
Read more →SRTSSensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026
Sensus Healthcare, Inc. will report its first quarter 2026 financial results on May 7, 2026. The company will hold a conference call at 4:30 PM ET to discuss these results and provide a business update. Participants can pre-register for the call or join via dial-in options.
Read more →SRTSSensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of Contract
Sensus Healthcare has initiated legal action against SkinCure Oncology for breach of contract. This lawsuit highlights significant disputes between the two companies, which could have financial implications. The ongoing legal battle may also divert attention from Sensus Healthcare's primary operations.
Read more →SRTSSensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed Base
Sensus Healthcare has launched Sensus Link, a cloud-based software solution designed to enhance the operational capabilities of its SRT-100 system. This initiative aims to improve workflow and treatment documentation for users, while also creating a recurring revenue opportunity. The company plans to roll out Sensus Link commercially in 2026, targeting both new and existing customers.
Read more →SRTSSensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology
Sensus Healthcare has launched a new program, Sensus Healthcare Financial Services, aimed at simplifying the acquisition of its superficial radiotherapy systems for dermatology practices. This initiative offers flexible financing options and is designed to enhance financial visibility and reimbursement certainty. The program is expected to streamline the purchasing process, making it more accessible for healthcare providers.
Read more →SRTSSensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer 2026 CMS Physician Fee Schedule Final Rule provides a 300% per-f
Sensus Healthcare reported its fourth quarter financial results for 2025, highlighting the publication of dedicated CPT codes for SRT treatments, which significantly boost reimbursement rates. Despite shipping 14 systems in Q4, the company faced a revenue decline from $13.1 million in Q4 2024 to $4.9 million due to reduced sales to its largest customer. Notably, the company experienced an increase in patient treatments, with utilization rising over eight-fold compared to 2024. With a strong balance sheet and expectations of improved shipment performance in early 2026, Sensus aims for full-year profitability.
Read more →SRTSSensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026
Sensus Healthcare, Inc. will report its fourth quarter and full year 2025 financial results on February 12, 2026. A conference call will follow at 4:30 p.m. Eastern time, where management will discuss the results and provide a business update. Participants can pre-register for the call or join via dial-in options.
Read more →SRTSSensus Healthcare Appoints Larry Biscotti to its Board of Directors BOCA RATON, Fla. - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive a
Sensus Healthcare, Inc. has appointed Larry Biscotti to its Board of Directors, enhancing its leadership team with his over 25 years of experience in medical devices and healthcare technology. Biscotti, who currently oversees imaging for GE Healthcare in the U.S. and Canada, is expected to contribute significantly to Sensus' strategic direction and commitment to innovative treatment solutions. His previous experience includes leadership roles at several renowned medical technology firms. This appointment reflects Sensus Healthcare's dedication to improving patient outcomes through advanced, patient-centric treatments.
Read more →SRTS▲ +9.3%on this news
Sensus Healthcare Appoints Eric Sachetta to its Board of Directors Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence BOCA RATON, Fla. (
Sensus Healthcare has appointed Eric Sachetta to its Board of Directors, succeeding the late Bill McCall. Sachetta, known for his extensive experience in financial services and organizational leadership, is expected to contribute significantly to the company's growth and strategic direction. He has previously led various initiatives in financial planning and has a strong track record in mentoring. Sensus Healthcare continues to innovate in non-invasive treatments for skin cancer and keloids, aiming for superior clinical outcomes.
Read more →SRTSSensus Healthcare Reports Third Quarter 2025 Financial Results Centers for Medicare & Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer Revenues of
Sensus Healthcare reported its financial results for the third quarter of 2025, marking revenues of $6.9 million, a decline from $8.8 million in Q3 2024. A significant development was the introduction of dedicated CPT codes by CMS for superficial radiotherapy (SRT) aimed at treating non-melanoma skin cancer, which is expected to enhance reimbursement processes. Despite positive advancements in product adoption and international interest, the company faced challenges with decreased sales volumes and lower gross margins compared to the previous year.
Read more →SRTSSensus Healthcare, Inc. Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated an investigation into possible securities fraud related to Sensus Healthcare, Inc. (SRTS) and may file a class action lawsuit on behalf of investors. This comes after Sensus reported disappointing financial results for Q2 2025, including a significant loss per share and a sharp decline in revenue. Following the announcement, Sensus's stock price fell by over 35%, prompting concerns among investors regarding potential losses.
Read more →SRTSSensus Healthcare Reports Second Quarter 2025 Financial Results Shipped 19 SRT systems during the quarter, including four to China Revenues of $7.3 million FDA treatment volume increased 27% over the first quarter Exited
Sensus Healthcare, Inc. has reported its financial results for the second quarter of 2025, indicating revenues of $7.3 million, down from $9.2 million in the same quarter last year. The company shipped 19 SRT systems and saw a 27% increase in FDA treatment volume over the previous quarter. However, gross margins have decreased significantly, and a proposed reimbursement policy could impact future sales. Despite these challenges, management believes that the company's strategic initiatives are gaining traction.
Read more →SRTSSensus Healthcare Reports First Quarter 2025 Financial Results 21 SRT systems shipped during the quarter; revenues of $8.3 million 65% increase in treatment volume from FDAs over preceding quarter Profitability forecast
Sensus Healthcare, Inc. (SRTS) announced its financial results for Q1 2025, reporting revenues of $8.3 million, down from $10.7 million in the same period last year. Despite this decrease, the company demonstrated a 65% increase in treatment volume and expressed confidence in its profitability for the upcoming quarters. Sensus's investments in marketing and research are expected to enhance growth, alongside participation in several dermatology conferences. However, the company faced a net loss of $2.6 million, contrasting with last year's profit of $2.3 million.
Read more →SRTSSensus Healthcare Buys Back Shares BOCA RATON, Fla. (
Sensus Healthcare, Inc. has announced the resumption of its share repurchase program, authorized by its Board of Directors, allowing the purchase of up to $3 million of its common stock. The company's CEO, Joe Sardano, highlighted this move as an opportunity to return capital to shareholders while investing in growth initiatives. Previous share repurchase activity under this program occurred in 2022, with over 9,427 shares already bought back. The program's specifics regarding timing and execution will be determined by management based on market conditions and company needs.
Read more →SRTS▲ +6.5%on this news· ran to -28% by day 3
Sensus Healthcare Reports Fourth Quarter and Full Year 2024 Financial Results Shipped a record 39 SRT systems during the quarter; revenues of $13.1 million Achieved fifth consecutive quarter of profitability; diluted EPS
Sensus Healthcare, Inc. reported strong financial results for the fourth quarter and full year 2024, with revenues reaching $13.1 million and a fifth consecutive quarter of profitability. The company shipped a record 39 SRT systems in the fourth quarter, demonstrating increased adoption of their technology. However, Sensus anticipates that sales in the first quarter of 2025 may decline compared to the previous year due to seasonal softening and potential impacts from marketing events. Overall, the company remains focused on expanding its market presence and product offerings.
Read more →SRTSPompano Veterinary Oncology Partners with Sensus Healthcare to Provide First Superficial Radiotherapy Services in a Mobile Configuration
Sensus Healthcare has partnered with Pompano Veterinary Oncology to introduce mobile superficial radiotherapy (SRT) for treating companion animals in South Florida. This innovative service aims to provide high-quality cancer treatment while minimizing stress for pets by offering home visits and clinic services. The SRT-100 system will enhance the clinic's existing oncology offerings.
Read more →SRTS▲ +10.1%on this news
REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
Sensus Healthcare reported a significant increase in revenues for Q3 2024, with a 127% rise compared to Q3 2023. The company achieved profitability and signed multiple agreements under its new revenue-sharing model. Management anticipates continued growth driven by the demand for SRT treatments for skin cancer. The company also highlighted the potential of its proprietary software in enhancing operational efficiency.
Read more →About Sensus Healthcare, Inc.
Headquarters851 BROKEN SOUND PARKWAY NW, BOCA RATON, FL, 33487
BIOPHARMAWATCH ELITE PLUS
Trade the next SRTS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime